Biochemical Data
In CD patients, the serum calcium and phosphate values adopted were those values measured on a day during 2 consecutive dialyses. The calcium -phosphate product was calculated. Serum cholesterol subfractions (total, lowdensity lipoprotein (LDL), and high-density lipoprotein (HDL)) and triglycerides were also evaluated.
Statistical Analysis
Data are expressed as mean ± SD. Statistical analysis was performed using SPSS, Version 10.0J (Chicago, IL, USA) or StatView 4.54 (Abacus, CA, USA). Group comparisons used the unpaired t-test, the Mann-Whitney test as appropriate for numerical data, and the chi-square test for categorical data. Baseline and follow-up studies were compared using the paired t-test and the Wilcoxon matched pairs signed rank test as appropriate. A value of p<0.05 was considered statistically significant.
Results
A total of 54,981 patients were tabulated. Of these, 16 patients with AS on CD (mean age of 68±10 years) and 82 non-dialysis patients with AS (73±11 years) were enrolled in this study.
The etiology of AS was considered as degenerative in 15 patients and unclassified in 1 of the CD patients and degenerative in 54, rheumatic in 6, bicuspid in 3, and unclassified in 19 of the non-dialysis patients. 3 The etiology of chronic renal failure was chronic glomerulonephritis in 10 patients, diabetic nephropathy in 3, malignant hypertension in 1, and unknown in 2.
Thirteen (16%) patients in the non-dialysis group had received statins for hyperlipidemia.
No difference was shown in mean age, sex ratio, and prevalence of diabetes mellitus. Hyperlipidemia was not present in the CD patients. The duration of dialysis was 89±100 months (ranging from 3.4 to 302 months) at entry; 13 of the 16 CD patients underwent hemodialysis and 3 underwent peritoneal dialysis. In the biochemical data, the CD patients had lower serum lipid values, lower serum calcium values and higher serum phosphate values, resulting in an increased calcium -phosphate product in these patients (Table 1) . Echocardiographic data are summarized in Table 2 . At entry, the peak transaortic valvular velocity or calculated peak pressure gradient was lower in CD patients than in the non-dialysis patients. There was no difference between the groups in LV end-diastolic dimension, %FS, left atrial dimension, wall thickness, or calculated aortic valvular area. Mitral annular calcification was more prevalent in CD patients, but the prevalence of moderate or severe aortic valve calcification was similar in both groups.
Follow-up echocardiographic examination was performed at a mean interval of 32±17 months in the CD patients and 40±23 months in the non-dialysis patients (NS). Heart rate was more rapid in CD patients. As at the time of entry, no difference was shown in LV end-diastolic dimension, %FS, left atrial dimension, or wall thickness. Peak transaortic valvular velocity or peak pressure gradient increased significantly in both groups and there was no difference in those values at the follow-up examination (Fig 1) . Calculated aortic valve area also decreased significantly, but no difference was present in the follow-up values. On the other hand, the progression rate of peak velocity was higher and that of peak pressure gradient tended to be higher in the CD patients than in the non-dialysis patients. Decreasing rate of aortic valvular area was increased in CD patients (Fig 2) . The calcification of the aortic valve was scored as more severe at the follow-up examination in CD patients: grade 3 in 3, and grade 4 in 7 (Fig 3) .
Statin treatment had no effect on the echocardiographic data in the non-dialysis patients.
With regard to outcome, 12 (75%) of the 16 CD patients and 23 (28%) of the 82 non-dialysis patients died (p< 0.001): there were 7 cases of sudden death or cardiac death (58%) in the CD group and 17 (74%) in the non-dialysis group. Fifteen non-dialysis patients (18%) underwent aortic valve replacement, but only 2 CD patients (12%) had aortic valve surgery.
Discussion
In this retrospective case -control study, we have shown that AS progresses rapidly and the prognosis is poor in CD patients. Calcium deposition on the aortic valve is thought to be an important cause of the acceleration.
The prevalence of AS in the general population is unclear and increases in the elderly. It is considered that the incidence of AS in CD patients is much greater than in a control population of the same age. 7 Straumann et al reported that 8 (13%) out of 62 patients aged 55 on CD had moderate AS. 8 A few studies of the progression of AS in patients on hemodialysis have been reported. Perkovic et al studied 28 dialysis patients with AS and it progressed more rapidly in the dialysis patients than in the controls according to the change in valve area (-0.19 vs -0.07 cm 2 /year) and change in peak transvalvular gradient (6.5 vs 3.9 mmHg/year) with a mean follow-up of 1.6 years in the dialysis patients and 2.6 years in the controls. 4 In our study, the mean yearly progression rate was -0.14 cm 2 in valve area and 11.8 mmHg (1.72 m/s) in peak gradient (velocity) with a mean followup of 2.7 years in CD patients. Wongpraparut et al demonstrated that the average rate of decline in aortic valvular area was 0.38 cm 2 /year in 6 elderly patients with AS on CD. 9 Rosenhek et al evaluated 128 patients with asymptomatic, severe AS and concluded that the patients with moderately or severely calcified aortic valves and a rapid rate of progression (>0.3 m/s per year) had poor prognosis. 3 In our study the progression rate was approximately 2-fold that of the AS patients on CD when compared with non-dialysis patients with AS.
Aortic valve calcification is also accelerated in CD patients. 4, 10, 11 Ectopic calcification is difficult to manage in patients with chronic renal failure or on CD and an increased calcium -phosphate product, secondary hyperparathyroidism, and excess vitamin D etc are thought to be the responsible factors for calcium deposition. 12 Accelerated calcium deposition not only in the coronary arteries but also on the aortic valves is a morbid problem in CD patients 13 and no specific remedy currently exists. The calcium -phosphate product was increased in the present CD patients.
Hypercholesterolemia might be a risk factor for the development and progression of calcific AS, 14, 15 although recent studies throw doubt on this hypothesis. Bellamy et al showed no correlation between serum cholesterol level and AS progression, 16 and in the present study, cholesterol subfractions were lower in the CD patients, which may be related to their general condition or a poor nutritional state.
When should we decide on aortic valve replacement in patients with AS on CD? 17 There are many difficulties in addition to AS and LV function: age, low nutritional state, anemia, hormonal or electrolyte abnormalities, calcium deposition on other organs, and the high possibility of concomitant coronary artery disease. The prognosis for CD patients is poor; the 1-and 5-year survival rates of CD patients are 87.3% and 61.4%, respectively, in Japan, 5 and 79.1% and 34.3% in the US. 18 In our study, 75% of the AS patients on CD died during a mean follow-up of 2.7 years and approximately 60% of cases were sudden death or cardiac death. Otto et al studied 123 asymptomatic patients with AS and showed that the patients with a jet velocity >4.0 m/s at entry had a high likelihood of operative indication within 2 years. 19 In our study the progression rate of AS (≈12 mmHg/year in peak gradient) was approximately 2-fold greater in the CD patients compared with the non- dialysis patients. The mean value of the peak velocity at follow-up was at most 4.1 m/s in CD patients. Operative timing may be too late if we hesitate on aortic valve replacement until peak velocity exceeds 4 m/s in considerable number of AS patients on CD. Early operative decisionmaking should be done even if the transvalvular peak velocity does not exceed 4 m/s in patients with AS on CD if the other conditions are acceptable. A large-scale, prospective study is necessary to evaluate the clinical feasibility or propriety of early operation in such patients.
In this study, the operative rate was relatively low in the non-dialysis patients as their mean age was already over 70 years at entry. Aging and/or concomitant coronary artery disease will be the main obstacles to surgical treatment. 20 Recent studies have suggested that statin treatment is associated with slower progression of AS, 16, 21, 22 but no effects were shown in the 13 non-dialysis patients taking statins in our study.
Electron beam computed tomography or multidetector computed tomography, which has been recently used for detecting coronary artery calcification, 23, 24 is not sensitive enough to diagnose aortic valve calcification. 23, 25 Serial echocardiography is currently feasible for assessing the severity of aortic valve calcification and AS.
Study Limitations
Our study was retrospective, with a relatively small sample, and in a single center. We used the transvalvular velocity as a representative value of AS progression because it could be measured in all the patients, whereas the aortic valve area could not. However, most studies have adopted the jet velocity as an evaluation of AS severity because of its clinical convenience and reproducibility. There was individual variability in the rate of peak velocity progression (Fig 4) , 19 which is influenced by various factors such as heart rate, afterload, the angle of the ultrasonic beam, the echocardiographer's experience etc. We used the first and last values in this clinical study. The transaortic valvular velocity decreases when the LV function is compromised in severe AS. No difference was present in the LV contractility between the 2 groups in the present study.
Conclusions
It appears that AS progressed rapidly in CD patients and therefore early aortic valve replacement should be considered.
